Boston Scientific's TAXUS Trials Set Standard for Evidence-Based Medicine

Strategic Insights -

Boston Scientific's TAXUS clinical trials have been recognized by the European Society of Cardiology (ESC) for providing definitive evidence for treatment decisions in cardiology. The ESC guidelines emphasize the need for large-scale, multi-center, randomized, controlled trials with adequately powered primary clinical endpoints. Boston Scientific's TAXUS IV, V, and VI trials meet these criteria, demonstrating the company's commitment to clinical sciences and evidence-based decision-making. The TAXUS stent system is the global market leader in drug-eluting stent systems, with the TAXUS Liberte system featuring the company's next-generation Liberte coronary stent.

Key Takeaways:

  • Boston Scientific's TAXUS IV, V, and VI trials were cited as examples of definitive clinical evidence for treatment decisions in cardiology.
  • The ESC guidelines emphasize the need for large-scale, multi-center, randomized, controlled trials with adequately powered primary clinical endpoints.
  • Boston Scientific's TAXUS stent system is the global market leader in drug-eluting stent systems.
  • The TAXUS Liberte system features the company's next-generation Liberte coronary stent.
  • Prof. Sigmund Silber, Chairman of the ESC PCI taskforce, stated that physicians need to make decisions based on clinical outcomes as a primary endpoint.
  • Non-blinded, single-center trials are not sufficient for instructing treatment decisions or making DES comparisons.
  • Mary E. Russell, M.D., Chief Medical Officer at Boston Scientific, emphasized the company's commitment to clinical sciences and evidence-based decision-making.
  • The European Society of Cardiology represents over 45,000 cardiology professionals across Europe and the Mediterranean region.

Statistics:

  • 45,000: Number of cardiology professionals represented by the European Society of Cardiology.
  • 3: Number of Boston Scientific's drug-eluting stent clinical trials (TAXUS IV, V, and VI) recognized by the ESC.
  • 5: Total number of trials cited in the ESC guidelines.
  • 2003: Year the TAXUS Express2 system received CE Mark in Europe.
  • 2004: Year the TAXUS Express2 system received U.S. FDA approval.
  • 2005: Year the TAXUS Liberte paclitaxel-eluting stent system was launched in 18 countries.
  • 2008: Projected year for the launch of the TAXUS Liberte system in the United States, pending regulatory approval.

Sources:

  • European Society of Cardiology (ESC)
  • Boston Scientific Corporation
  • U.S. Food and Drug Administration (FDA)
  • Milkin, $650-8569 (Boston Scientific Investor Relations)
  • Donovan, $650-8541 (Boston Scientific Media Relations)
  • Boston Scientific Corporation Web site: http://www.bostonscientific.com/